» Articles » PMID: 22686277

Immunohistochemical Investigation of Cell Cycle and Apoptosis Regulators (survivin, β-catenin, P53, Caspase 3) in Canine Appendicular Osteosarcoma

Abstract

Background: Osteosarcoma (OSA) represents the most common canine primary bone tumour. Despite several pathways have been investigated so far, few molecules have been identified as prognostic tools or potential therapeutic targets, and there is still the need to find out molecular pathways with specific influence over OSA progression to facilitate earlier prognosis and treatment.Aims of the present study were to evaluate the immunohistochemical pattern and levels of expression of a panel of molecules (survivin, β-catenin, caspase 3 -inactive and active forms- and p53) involved in cell cycle and apoptosis regulation in canine OSA samples, known to be of interest in the study also of human OSA, and to detect specific relations among them and with histological tumour grade, disease free interval (DFI) and overall survival (OS).

Results: Nuclear β-catenin immunostaining was detected in normal osteoblasts adjacent to the tumour, and in 47% of the cases. Cytoplasmic and/or membranous immunostaining were also observed. Nuclear survivin and p53 positive cells were found in all cases. Moderate/high cytoplasmic β-catenin expression (≥10% positive cells) was significantly associated with the development of metastasis (P = 0.014); moderate/high nuclear p53 expression (≥10% positive cells) was significantly associated with moderate/high histological grade (P = 0.017) and shorter OS (P = 0.049). Moderate/high nuclear survivin expression (≥15% positive cells) showed a tendency toward a longer OS (P = 0,088).

Conclusions: The present results confirmed p53 as negative prognostic marker, while suggested survivin as a potential positive prognostic indicator, rather than indicative of a poor prognosis. The detection of nuclear β-catenin immunostaining in normal osteoblasts and the absent/low expression in most of the OSAs, suggested that this pathway could not play a major role in oncogenic transformation of canine osteoblasts. Further studies are needed to confirm these hypotheses.

Citing Articles

Wnt/β-catenin signaling pathway: an attractive potential therapeutic target in osteosarcoma.

Ding Y, Chen Q Front Oncol. 2025; 14:1456959.

PMID: 40028002 PMC: 11867957. DOI: 10.3389/fonc.2024.1456959.


Validation of p53 Immunohistochemistry (PAb240 Clone) in Canine Tumors with Next-Generation Sequencing (NGS) Analysis.

Brunetti B, de Biase D, Dellapina G, Muscatello L, Ingravalle F, Tura G Animals (Basel). 2023; 13(5).

PMID: 36899756 PMC: 10000222. DOI: 10.3390/ani13050899.


Recent Advances in the Discovery of Biomarkers for Canine Osteosarcoma.

Luu A, Wood G, Viloria-Petit A Front Vet Sci. 2021; 8:734965.

PMID: 34660770 PMC: 8517113. DOI: 10.3389/fvets.2021.734965.


Immunohistochemical detection of p53 and pp53 Ser in canine hemangiomas and hemangiosarcomas located in the skin.

Garcia-Iglesias M, Cuevas-Higuera J, Bastida-Saenz A, de Garnica-Garcia M, Polledo L, Perero P BMC Vet Res. 2020; 16(1):239.

PMID: 32660487 PMC: 7359283. DOI: 10.1186/s12917-020-02457-6.


Identification of Differentially Expressed Genes under the Regulation of Transcription Factors in Osteosarcoma.

Liu Y, Guan J, Chen X Pathol Oncol Res. 2018; 25(3):1091-1102.

PMID: 30411296 DOI: 10.1007/s12253-018-0519-0.


References
1.
Clevers H . Wnt/beta-catenin signaling in development and disease. Cell. 2006; 127(3):469-80. DOI: 10.1016/j.cell.2006.10.018. View

2.
Shoeneman J, Ehrhart 3rd E, Eickhoff J, Charles J, Powers B, Thamm D . Expression and function of survivin in canine osteosarcoma. Cancer Res. 2011; 72(1):249-59. DOI: 10.1158/0008-5472.CAN-11-2315. View

3.
Kow K, Thamm D, Terry J, Grunerud K, Bailey S, Withrow S . Impact of telomerase status on canine osteosarcoma patients. J Vet Intern Med. 2008; 22(6):1366-72. DOI: 10.1111/j.1939-1676.2008.0175.x. View

4.
Kansara M, Tsang M, Kodjabachian L, Sims N, Trivett M, Ehrich M . Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest. 2009; 119(4):837-51. PMC: 2662557. DOI: 10.1172/JCI37175. View

5.
Fodde R, Brabletz T . Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol. 2007; 19(2):150-8. DOI: 10.1016/j.ceb.2007.02.007. View